View of Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

Return to Article Details Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity Download Download PDF